Literature DB >> 21470114

Application of cell-free hemolymph of horseshoe crab in antimicrobial drug screening.

Ruijuan Du1, Bow Ho, Jeak Ling Ding.   

Abstract

Horseshoe crabs are an ancient invertebrate which possesses powerful innate immune defense against microbes. The simplicity, specificity and rapidity of its antimicrobial response have accorded the horseshoe crab as an excellent animal model from which immune responsive tissues may be procured for biomedical research. Such usefulness is exemplified by the extensive application for nearly four decades, of the limulus amebocyte lysate (LAL) for sensitive detection of endotoxin in the medical industry. Apart from the amebocytes, the cell-free hemolymph (CFH) of this arthropod offers a large repertoire of evolutionarily conserved proteins, which are highly sensitive to pathogens. This makes the hemolymph an ideal physiological microenvironment for simulating an in vitro infection. We therefore propose to employ the CFH as a quick and convenient tool for antimicrobial drug screening in vitro. This specific drug screening system also provides further optimization of drug design, and selection of drugs with antioxidant properties. Being an easily accessible natural resource, and allowing high-throughput screening with uniform and reliable data output, the horseshoe crab CFH provides a desirable physiological milieu for drug screening and development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21470114     DOI: 10.2174/138161211795703717

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  1 in total

1.  Microsatellite Loci of the Atlantic Horseshoe Crab (Limulus polyphemus) Reveal Inter-Localities Genetic Diversity in the Coastal Waters of the Eastern and Northern Yucatan Peninsula.

Authors:  Roberto Zamora-Bustillos; Juan José Sandoval-Gío; Héctor Javier Ortiz-León; Harold Villegas-Hernández; Gerardo Alfonso Avilés-Ramírez
Journal:  Biochem Genet       Date:  2022-10-17       Impact factor: 2.220

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.